BDX生命科学与高端医疗● Live Quotes Active

Becton, Dickinson and Company

No mega hedge funds in our coverage currently report a major 13F position in this stock

Live Price
24h Change
Mega Funds Holding
0/ 33 funds

Coverage: 0.0%

Avg Portfolio Weight
0%

-

Wall St Sentiment
0%Bullish
+0/0/-0
Total Tracked Shares
0shares

Based on SEC 13F filings

SGDC Dual-Core EngineSuper-Growth Dual-Core Radar

🚀BDX SGDC Quant Rating & Setup

Open SGDC Screener↗
4P Grade
C 级(60分)
RS Rating
66/ 99
Pattern Setup
Base Setup
Pivot Benchmark
$200.47Support: $185.43

📌 Business Moat Summary:Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

ℹ️
13F Hedge Fund Coverage NoticeNone of the 33 tracked mega hedge funds (e.g., Berkshire Hathaway, Bridgewater, Renaissance, Citadel) currently report a major 13F position in BDX.✦ Note: This stock is actively tracked by the SGDC Super-Growth Quant Engine (4P Grade C, RS Rating 66).

📈8-Quarter Institutional Ownership Evolution

Historical trajectory of institutional holders and allocation weight across the last 8 quarters

Select Quarter:
0% 均仓
0 f2026 Q2
0% 均仓
0 f2026 Q1
0% 均仓
0 f2025 Q4
0% 均仓
0 f2025 Q3
0% 均仓
0 f2025 Q2
0% 均仓
0 f2025 Q1
0% 均仓
0 f2024 Q4
0% 均仓
0 f2024 Q3
2026 Q2|Report Date: 2026-06-30
Holding Funds: 0 家Total Shares: 0Avg Weight: 0%

🏛️Institutional Investors Holding this Stock

Examine each hedge fund holding this ticker, weight, shares, and recent action

Sort by:
Manager / FundFund AUMWeightShares HeldActionAction
No tracked mega hedge funds currently hold this stock.
🎯

Want to see Wall Street's Top 50 Consensus Buys?

Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.

Go to Consensus Screener →

⚡Planning to trade BDX?

Add this symbol to your private journal or dividend tracker to monitor institutional moves.

BDX (Becton, Dickinson and Company) Institutional 13F Ownership & SGDC Growth Analysis 2026 | WhaleTracker